Stamakort
Research OnlyA peptide bioregulator developed by Russian scientist Vladimir Khavinson for gastric mucosa support. Claimed to modulate stomach lining gene expression and support digestive function. No Western clinical validation exists.
Gastric peptide · Stomach bioregulator · Gastric mucosa peptide
Preclinical evidence only
- Preclinical
- 83%
- Clinical
- 0%
Based on 6 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 12: no human data of any tier (1A=6 animal-only), best evidence at high risk of bias (1B=2, uncontrolled Russian animal models), zero human N (1C=0), indirect animal surrogate evidence (1D=2), and only a weak/undefined preclinical base (1E=2 — the compound's own sequence is not publicly characterized). Mechanism 24: gastric-mucosa gene-modulation target is inferred with no binding data (2A=10), pathway only partially sketched via the broader Khavinson short-peptide framework (2B=7), no dose-response for the compound (2C=3), in-vivo mammalian context by class extrapolation (2D=4). Plausibility 48: gastric gene-modulation -> digestive support has >=1 unproven intermediate link (3A=13); coherent with real same-class gastric-peptide biology — Khavinson peptide T-34 normalizes antioxidant/anti-inflammatory gene expression in gastric ulcer (PMID 22803148) and pineal peptides regulate gastric endocrine cells (PMID 11276313) (3B=16, 3C=9); tightly scoped gastric claim (3D=10). Global Coverage 12: single Russian lab/author group with no independent replication (4A=4), one country/institution (4B=4), <5 studies under this name (4C=4), no governance approval anywhere (4D=0). Community Experience 15: negligible documented use (5A=3), short/unclear track record (5B=5), no reports to assess consistency (5C=3), no recurring adverse signal but only because exposure is negligible (5D=4). Effectiveness not established: no quantified human efficacy estimate and no meaningful community effect signal. Cited PMIDs are the closest real class-level gastric-bioregulator literature; none is stamakort-specific (no PubMed-indexed studies exist under that name).
Mechanism of Action
Stamakort is proposed to support gastric mucosa through peptide bioregulation mechanisms developed by Vladimir Khavinson.
Proposed Mechanisms
- Mucosal Gene Modulation - Claimed to regulate gene expression in gastric mucosa cells
- Protective Function - Proposed effects on stomach lining integrity
- Digestive Support - Claimed involvement in gastric secretory function
Important Limitations
- No Western clinical validation or regulatory approval
- Limited Russian preclinical data only
- Amino acid sequence not fully characterized in public literature
- NOT a treatment for ulcers or gastric conditions
- No controlled human clinical trials
Chonluten
CompatibleBoth target digestive system - Chonluten for GI tract broadly, Stamakort specifically for gastric mucosa.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Stamakort
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
EVX-01
EVX01 · Evaxion EVX-01 · AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1/2 data in melanoma showed a 67% objective response rate (8/12; 6 partial, 2 complete) when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.